The regulatory approval of the oral estrogen receptor antagonist is for patients whose cancer has an ESR1 mutation and has ...
KOMET-001 in R/R NPM1-m AML met its primary endpoint with ziftomenib monotherapy demonstrating significant clinical benefit and deep responses – – Consistent activity across pre-specified subgroups, ...
(OS) observed at 9 months; standard of care benchmark is ~47% - - 53% progression-free survival (PFS) observed at 9 months; standard of care benchmark is ~29% - - Company expects ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback